[1]王 秦,张家佳,刘成桂,等.高表达IL-12卵巢癌细胞的建立[J].医学信息,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
　WANG Qin,ZHANG Jia-jia,LIU Cheng-gui,et al.Establishment of High Expression of IL-12 Ovarian Cancer Cells[J].Journal of Medical Information,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
点击复制

高表达IL-12卵巢癌细胞的建立()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年21期
页码:
78
栏目:
论著
出版日期:
2019-11-01

文章信息/Info

Title:
Establishment of High Expression of IL-12 Ovarian Cancer Cells
文章编号:
1006-1959（2019）21-0078-04
作者:
王 秦1; 张家佳2; 刘成桂1; 曹登成1
（电子科技大学医学院附属妇女儿童医院·成都市妇女儿童中心医院检验科1，妇产科2，四川 成都 611731）
Author(s):
WANG Qin1; ZHANG Jia-jia2; LIU Cheng-gui1; CAO Deng-cheng1
(Department of Clinical Laboratory1,Department of Obstetrics and Gynecology2,Women and Children's Hospital,University of Electronic Science and Technology of China·Chengdu Women and Children Center Hospital,Chengdu 611731,Sichuan,China)
关键词:
IL-12; 卵巢癌; 高表达; SKOV3细胞
Keywords:
IL-12; Ovarian cancer; High expression; SKOV3 cells
分类号:
R737.3
DOI:
10.3969/j.issn.1006-1959.2019.21.024
文献标志码:
A
摘要:
目的 建立高表达IL-12的卵巢癌细胞，为后续IL-12治疗卵巢癌奠定基础。方法 将人卵巢癌细胞株SKOV3分为SKOV3组、SKOV3/GFP组和SKOV3/IL-12组三个实验组，SKOV3组不做任何处理，SKOV3/GFP组给予空载病毒感染SKOV3细胞，SKOV3/IL-12组给予IL-12基因腺病毒感染SKOV3细胞。腺病毒感染SKOV3细胞48 h后，使用荧光显微镜检测三个实验组的感染效率，RT-PCR检测各组SKOV3细胞IL-12 p35、p40 mRNA水平的表达量，ELISA方法检测感染72 h后各组细胞培养液中IL-12的含量。结果 SKOV3/GFP和SKOV3/IL-12组中的SKOV3细胞均可以在荧光显微镜下观察到绿色荧光，而SKOV3组没有观察到绿色荧光，SKOV3/GFP和SKOV3/IL-12组的感染效率分别是（97±1）%和（95±1）%，差异具有统计学意义（P＜0.05）；RT-PCR结果表明，与SKOV3和SKOV3/GFP组相比较，SKOV3/IL-12组可以成功扩增出IL-12 p35、p40亚基，差异具有统计学意义（P＜0.05）；ELISA结果表明，与SKOV3和SKOV3/GFP组比较，SKOV3/IL-12组能够高表达IL-12P70蛋白，差异具有统计学意义（P＜0.05）。结论 成功建立了高表达IL-12的卵巢癌SKOV3细胞，为进一步采用IL-12进行卵巢癌的免疫治疗打下了基础。
Abstract:
Objective To establish ovarian cancer cells with high expression of IL-12, and lay a foundation for the subsequent treatment of ovarian cancer with IL-12. Methods The human ovarian cancer cell line SKOV3 was divided into three groups: SKOV3 group, SKOV3/GFP group and SKOV3/IL-12 group. SKOV3 group was not treated. SKOV3/GFP group was given virus-infected SKOV3 cells,The SKOV3/IL-12 group was administered with IL-12 gene adenovirus to infect SKOV3 cells. After infection with SKOV3 cells for 48 h, the infection efficiency of the three experimental groups was detected by fluorescence microscopy. The expression levels of IL-12 p35 and p40 mRNA in SKOV3 cells were detected by RT-PCR. ELISA method was used to detect the content of IL-12 in the culture medium of each group 72 h after infection.Results The SKOV3 cells in the SKOV3/GFP and SKOV3/IL-12 groups were observed to have green fluorescence under the fluorescence microscope, while the green fluorescence was not observed in the SKOV3 group, and the infection efficiencies in the SKOV3/GFP and SKOV3/IL-12 groups were ( 97±1)% and (95±1)%, the difference was statistically significant (P<0.05);RT-PCR results showed that compared with SKOV3 and SKOV3/GFP group, ILOV p35 and p40 subunits could be successfully amplified in SKOV3/IL-12 group, the difference was statistically significant (P<0.05); ELISA results showed Compared with SKOV3 and SKOV3/GFP group, SKOV3/IL-12 group can express IL-12P70 protein with high expression,the difference was statistically significant (P<0.05).Conclusion The ovarian cancer SKOV3 cells with high expression of IL-12 have been successfully established, which lays a foundation for further immunotherapy of ovarian cancer with IL-12.

参考文献/References:

[1]Ledermann JA,Raja FA,Fotopoulou C,et al.Newly diagnosed and relapsed epithelial ovarian carcinoma：ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv259. [2]Eisenhauer EA.Real-world evidence in the treatment of ovarian cancer[J].Ann Oncol,2017,28(Suppl_8):viii61-viii65. [3]奉颖,肖梅珠,张紫寒,等.卵巢癌微环境中巨噬细胞和LPA的研究进展[J/OL].现代妇产科进展,2019(10):1-8[2019-10-16].http://kns.cnki.net/kcms/detail/37.1211.r.20190704.1323. 002.html. [4]吴小华,张剑,尹如铁,等.优化卵巢癌Ⅰ期临床研究管理中国专家经验[J].中国癌症杂志,2019,29(5):321-327. [5]Nair RE,Jong YS,Jones SA,et al.IL-12+ GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in HER-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity[J].J Immunother,2006,29(1):10-20. [6]成凤,匡文斌,王秦,等.携人IL-12基因腺病毒的构建及其对Hep3B细胞增殖及TGF-β表达的影响[J].中国免疫学杂志,2012,8(5):402-406. [7]张晓妮,胜利.IL-12抗肿瘤作用机制的研究进展[J].医学综述,2018,24(2):301-305. [8]Issaranggun Na Ayuthava B,Everts V,Pavasant P.The immunopathogenic and immunomodulatory effects of interleukin-12 in periodontal disease[J].Eur J Oral Sci,2018,126(2):75-83． [9]Kamensek U,Tesic N,Sersa G,et al.Clinically usable interleukin 12 plasmid without an antibiotic resistance gene:functionality and toxicity study in murine melanoma model[J].Cancers(Basel),2018,10(3):60. [10]Burkart C,Mukhopadhyay A,Shirley SA,et al.Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters[J].Gene Ther,2018,25(2):93-103. [11]Lampreht Tratar U,Kos S,Kamensek U,et al.Antitumor effect of antibiotic resistance gene-free plasmids encoding interleukin-12 in canine melanoma model[J].Cancer Gene Ther,2018,25(9-10):260-273． [12]盛敏佳,薛丽娟,王立岩,等.卵巢癌抗原冲击DC在体外对SKOV3细胞作用的研究[J].中国实验诊断学,2016,20(11):1811-1816. [13]Lenzi R,Edwards R,June C,et al.PhaseⅡ study of intraperitoneal recombinant interleukin-12(rhIL-12)in patients with peritoneal carcinomatosis (residual disease＜1 cm) associated with ovarian cancer or primary peritoneal carcinoma[J].J Transl Med,2007(5):66.

相似文献/References:

[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
　YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Journal of Medical Information,2018,31(21):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]揭嘉慧,张 颖.卵巢癌与非编码RNA研究进展[J].医学信息,2019,32(05):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
　JIE Jia-hui,ZHANG Ying.Progress in Research on Ovarian Cancer and Non-coding RNA[J].Journal of Medical Information,2019,32(21):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
　LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Journal of Medical Information,2019,32(21):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
　LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Journal of Medical Information,2019,32(21):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
　XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Journal of Medical Information,2019,32(21):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
[6]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
　ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Journal of Medical Information,2019,32(21):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[7]黄馨禾,董丹丹,刘 倩.PARP抑制剂在卵巢癌治疗中的研究现状[J].医学信息,2019,32(21):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
　HUANG Xin-he,DONG Dan-dan,LIU Qian.Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer[J].Journal of Medical Information,2019,32(21):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
[8]钟达媚,张 颖.PCG与卵巢癌关系的研究[J].医学信息,2020,33(01):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
　ZHONG Da-mei,ZHANG Ying.Study on the Relationship Between PCG and Ovarian Cancer[J].Journal of Medical Information,2020,33(21):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
[9]张晓黎,张 颖,陈国通,等.环状RNA在妇科恶性肿瘤中的研究进展[J].医学信息,2020,33(03):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]
　ZHANG Xiao-li,ZHANG Ying,CHEN Guo-tong,et al.Study of Circular RNA in Gynecological Malignancies[J].Journal of Medical Information,2020,33(21):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]
[10]魏绮琪,张 颖.miR-200c与卵巢癌关系的研究[J].医学信息,2020,33(03):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]
　WEI Qi-qi,ZHANG Ying.Study on the Relationship Between miR-200c and Ovarian Cancer[J].Journal of Medical Information,2020,33(21):53.[doi:10.3969/j.issn.1006-1959.2020.03.016]

更新日期/Last Update: 2019-11-01